Other languages Janux Therapeutics, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 03:16:29 2024-05-20 pm EDT			5-day change	1st Jan Change
47.92 ^USD	+1.73%		-3.98%	+347.34%

May. 08	Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating	MT
May. 08	Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Aktien New York: Dow erholt sich vor Start in die Berichtssaison	Apr. 11
Aktien New York: Dow schwächer vor Start in die Berichtssaison	Apr. 11
Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet	Apr. 11
Sector Update: Health Care Stocks Slipping Late Afternoon	Apr. 10
Sector Update: Health Care	Apr. 10
Janux Therapeutics Said to be Considering Sale	Apr. 10
Janux Therapeutics Q4 Net Loss Narrows, Revenue Decreases	Mar. 08
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08
Janux Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 08
Janux Therapeutics Prices $296.5 Million Offering of Common Stock, Pre-Funded Warrants	Feb. 29
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 27
Sector Update: Health Care	Feb. 27
Aktien New York: Börsen bleiben nahe Rekordhochs	Feb. 27
Top Midday Gainers	Feb. 27
Janux Therapeutics Shares Soar After Wedbush Boosts Price Target Following 'Positive' Data From Two Cancer Studies	Feb. 27
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday as Investors Await Key Data for Rate-Cut Hints	Feb. 27
Aktien New York Ausblick: US-Börsen weiter stabil am Rekordniveau	Feb. 27
Top Premarket Gainers	Feb. 27
Janux Therapeutics Discloses 'Positive' Data From Two Phase 1a Studies into Different Types of Cancers -- Shares Almost Double After Hours	Feb. 26

No results for this search